Another recent in vivo study showed that administration of the JNK inhibitor SP600125 resulted in cognitive deficit improvement in a transgenic AD mouse model by reducing Aβ production, inflammatory responses and synaptic loss (Zhou et al., 2015). The gene discussed is MAPK8; the disease is Alzheimer disease.